Tanasienko O A, Cheremshenko N L, Titova G P, Potebnya M G, Gavrilenko M M, Nagorna S S, Kovalenko N K
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine.
Exp Oncol. 2005 Dec;27(4):336-8.
The aim of the work was to evaluate in vivo the possible enhancement of efficacy of antitumor vaccine prepared on the base of cytotoxic lectine from B. subtilis B-7025 by its combination with probiotic mixture of Enterococcus faecium K-50 and Saccharomyces cerevisiae 14K or their metabolic products.
Experiments were carried out on the models of solid sarcoma 37 (S37) and metastatic Lewis lung carcinoma (3LL). Efficacy of treatment was evaluated by parameters of tumor growth, median survival time of experimental animals and volume of metastases.
We have shown that combined application of antitumor vaccine with pro-and/or prebiotic resulted in synergistic effect in the therapy S37-bearing mice, whilst in 3LL-bearing animals application of vaccine along with prebiotic inhibited metastasis by 2-2.5-fold compared to animals treated by vaccine only.
Application of pre- and probiotics (E. faecium K-50 and S. cerevisiae) markedly elevates efficacy of antitumor vaccine in vivo.
本研究旨在评估在体内，基于枯草芽孢杆菌B - 7025的细胞毒性凝集素制备的抗肿瘤疫苗，与粪肠球菌K - 50和酿酒酵母14K的益生菌混合物或其代谢产物联合使用时，是否可能增强其疗效。
实验在实体肉瘤37（S37）和转移性刘易斯肺癌（3LL）模型上进行。通过肿瘤生长参数、实验动物的中位生存时间和转移灶体积来评估治疗效果。
我们发现，抗肿瘤疫苗与益生菌和/或益生元联合应用，对荷S37小鼠的治疗产生协同效应，而在荷3LL动物中，与仅接种疫苗的动物相比，疫苗与益生元联合应用可使转移灶减少2至2.5倍。
益生元和益生菌（粪肠球菌K - 50和酿酒酵母）的应用显著提高了抗肿瘤疫苗在体内的疗效。
